DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eric Joseph - 2 Joseph - 1 JPMorgan Chase - 1 Andrew Steinman - 1 Richard Shane - 1 NMI - 1 Doug Anmuth's - 1 Mark Murphy - 1
Top related locs:
U.S 1H24
Top related orgs:
Beam Therapeutics - 1 TAM - 1 JPMorgan - 1 NMI Holdings - 1 Medicines - 1 Amazon - 1 Microsoft - 1

Search resuls for: "Eric Joseph"


3 mentions found


☆ This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
  + stars: | 2024-01-29 | by ( Pia Singh | ) www.cnbc.com   time to read: +3 min
JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from increased market share and a strong gene therapy pipeline. "We see BEAM outperforming our coverage over the mid-term, with current levels being an attractive entry point," the analyst said. The stock is down more than 4% so far this year, and has lost more than 42% over the past 12 months. BEAM 1Y mountain Beam stock. He added that BEAM-302 is "uniquely positioned" as a one-time genetic medicine for AATD, particularly given its success in preclinical trials.
Persons: Eric Joseph, Joseph Organizations: Beam Therapeutics, TAM Locations: U.S, 1H24
☆ These are JPMorgan’s favorite stock picks heading into November
  + stars: | 2023-11-01 | by ( Brian Evans | ) www.cnbc.com   time to read: +2 min
JPMorgan Chase parted with four stocks in its list of favorite picks heading into November, including an upscale athletic retailer. The bank made a single addition for November on its Analyst Focus List, highlighting food service stock Aramark . The bank also removed mortgage company NMI Holdings from the focus list, as well as oncology firm Revolution Medicines . Other stocks on the focus list include Capital One , included as a value stock, with a $111 per share price target. AMZN YTD mountain Amazon stock.
Persons: JPMorgan Chase, Andrew Steinman, Richard Shane, NMI, Eric Joseph, Doug Anmuth's, Mark Murphy, — CNBC's Michael Bloom Organizations: JPMorgan, NMI Holdings, Medicines, Amazon, Microsoft
☆ JPMorgan says this biotechnology stock can rally nearly 50% because of its drug pipeline
  + stars: | 2023-03-06 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
Vir Biotechnology has an underappreciated opportunity in the flu prevention market, JPMorgan said. He shaved $1 off his price target to $34, which still implies an upside of 48.9% from Friday's close. "Vir Biotechnology holds long-term pipeline opportunities across multiple infectious disease indications including hepatitis B, and Influenza A," he said in a note to clients Monday. He said the stock could see upside when the latest Peninsula study data hits, given it's expected to be a linear read-through from the young adult-focused earlier study. The stock has whiplashed in its first years as a publicly traded company, recording advances of 113% and 56.4% in 2020 and 2021, respectively.
0 next >>
Total: 3